特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
833128

米国の非腫瘍バイオ医薬品市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年

U.S. Non-oncology Biopharmaceuticals Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 224 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
米国の非腫瘍バイオ医薬品市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年
出版日: 2019年04月22日
発行: Coherent Market Insights
ページ情報: 英文 224 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

バイオ医薬品は、生物を用いて製造または合成される高分子タンパク質およびペプチドです。バイオ医薬品はさらに生物学的製剤とバイオシミラーに分類されます。

当レポートでは、米国の非腫瘍バイオ医薬品市場を調査し、市場の概要、製品タイプ・医薬品クラス・適応疾患別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、償還シナリオ、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 仮定
  • 略語

第2章 市場範囲

  • レポートの説明
  • 市場の定義と範囲
  • エグゼクティブサマリー
  • 市場スニペット:製品タイプ別
  • 市場スニペット:医薬品クラス別
  • 市場スニペット:適応疾患別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、市場動向

  • 市場力学
  • 成長要因
  • 阻害要因
  • 市場機会
  • 影響分析
  • 最近の製品承認/発売
  • 合併・買収のシナリオ
  • 規制シナリオ
  • 償還シナリオ
  • PEST分析
  • 市場の課題
  • 非腫瘍生物製剤上位10ブランドのシェア
  • 主要バイオ医薬品の投薬方法
  • 管理モードの分析
  • 疫学
  • PEST分析
  • ファイブフォース分析

第4章 米国の非腫瘍バイオ医薬品市場:製品タイプ別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • 市場動向:製品タイプ別
  • 生物学的製剤
  • バイオシミラー

第5章 米国の非腫瘍バイオ医薬品市場:医薬品クラス別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • 市場動向:医薬品クラス別
  • 血液因子
  • ボツリヌス毒素
  • コロニー刺激因子
  • 酵素補充療法
  • エリスロポエチン
  • 融合タンパク質
  • ヒト成長ホルモン
  • インターフェロン
  • モノクローナル抗体
  • 組換えヒトインスリン
  • ワクチン
  • その他

第6章 米国の非腫瘍バイオ医薬品市場:適応疾患別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • 市場動向:適応疾患別
  • 加齢性黄斑変性症
  • 貧血
  • 強直性脊椎炎
  • クローン病
  • 嚢胞性線維症
  • 糖尿病
  • 血友病
  • B型肝炎
  • 多発性硬化症
  • 骨粗鬆症
  • 乾癬
  • 乾癬性関節炎
  • 慢性関節リウマチ
  • 潰瘍性大腸炎
  • その他

第7章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Sanofi S.A.
    • Pfizer, Inc.
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol - Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • UCB Pharma
    • Teva Pharmaceutical Industries Ltd.
    • 武田薬品工業
    • AstraZeneca Plc
    • Mylan N.V.
    • LEO Pharma A/S
    • Boehringer Ingelheim GmbH
    • Alexion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Elusys Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB
    • Samsung Bioepis NL B.V.
    • Biogen Inc.
    • Theratechnologies Inc.

第8章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Biopharmaceuticals are complex, high molecular weight proteins and peptides that are produced or synthesized from living biological source. Biopharmaceuticals are further divided into biologics and biosimilars.

Biologics can be defined as molecules derived from the living cells such as microorganisms, or plant or animal cells and used in the treatment, diagnosis, or prevention of diseases. Most of the biologic molecules are very large, complex molecules, or mixture of molecules. The U.S. Food and Drug Administration (FDA) defines biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Non-oncology biopharmaceuticals are drugs which are indicated for treatment of a number of diseases except cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Market Dynamics

Frequent launch, approval, and presence of robust pipeline of novel biopharmaceutical products indicated for treatment of number of non-oncology indication is expected to drive the U.S. non-oncology biopharmaceuticals market growth over the forecast period. For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.

In March 2018, Theratechnologies Inc. and its partner TaiMed Biologics Inc. received the U.S. Food and Drug Administration (FDA) approval for its Trogarzo (ibalizumab-uiyk) Injection. In combination with other ARTs, Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.

Key players in the market are adopting inorganic growth strategies such as mergers and partnerships for the development of novel products or to expand their product portfolio by acquisition. Such frequent activities by key players is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. entered into an exclusive partnership to commercialize two of Celltrion's mAb biosimilar candidates in the U.S. and Canada.

In 2016, Shire plc. and Baxalta Incorporated entered into an agreement, under which Shire will combine with Baxalta. Baxalta has a well-established hematology portfolio based on its heritage and legacy of leadership in hemophilia. With this merger, the established company (Shire plc.) will strengthen its position in the market.

Furthermore, high prevalence of various chronic disorders such as diabetes, asthma, cardiovascular diseases, and arthritis in the U.S. is expected to increase demand for biopharmaceutical products and in turn support the non-oncology biopharmaceuticals market growth. For instance, according to the data published by Centers for Disease Control and Prevention (CDC), in 2017, over 100 million U.S. adults were suffering from diabetes or pre-diabetes.

Key features of the study:

  • This report provides in-depth analysis of U.S. non-oncology biopharmaceuticals market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the U.S. Non-oncology biopharmaceuticals market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The U.S. non-oncology biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the U.S. non-oncology biopharmaceuticals market

Detailed Segmentation:

  • U.S. Non-oncology Biopharmaceuticals Market, By Product Type :
    • Biologics
    • Biosimilars
  • U.S. Non-oncology Biopharmaceuticals Market, By Drug Class:
    • Monoclonal Antibody
    • Enzyme Replacement Therapy
    • Erythropoietin
    • Interferon
    • Colony-stimulating Factor
    • Botulinum Toxin
    • Fusion Protein
    • Vaccines
    • Human Recombinant Insulin
    • Blood Factors
    • Human Growth Hormone
    • Others
  • U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication:
    • Diabetes
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Multiple Sclerosis
    • Hemophilia
    • Anemia
    • Age-related Macular Degeneration
    • Hepatitis B
    • Cystic Fibrosis
    • Osteoporosis
    • Crohn's Disease
    • Ulcerative Colitis
    • Psoriasis
    • Ankylosing Spondylitis
    • Others (Cardiac diseases and others)
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol - Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • UCB Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Ltd
    • AstraZeneca Plc
    • Mylan N.V.
    • LEO Pharma A/S
    • Boehringer Ingelheim GmbH
    • Alexion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Elusys Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB
    • Samsung Bioepis NL B.V.
    • Biogen Inc.
    • Theratechnologies Inc.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Indication
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Recent Product Approval/Launch
    • Merger-Acquisition Scenario
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pest Analysis
    • Market Challenges
    • Top 10 Non-oncology Biologics Brand Share
    • Major Biopharmaceuticals Administration Method
    • Analysis Of Mode Of Administration
    • Epidemiology
    • Pest Analysis
    • Porter's Five Forces Analysis

4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Biologics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Biosimilars
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Blood Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Botulinum Toxin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Colony-stimulating Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Enzyme Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Erythropoietin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Fusion Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Recombinant Human Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Age-related Macular Degeneration
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Anemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Ankylosing Spondylitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Crohn's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hemophilia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Multiple Sclerosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Osteoporosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Psoriasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Psoriatic Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Rheumatoid Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Ulcerative Colitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

7. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bristol - Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • UCB Pharma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Takeda Pharmaceutical Company Ltd
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • LEO Pharma A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Alexion Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Elusys Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Swedish Orphan Biovitrum AB
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Samsung Bioepis NL B.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Theratechnologies Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.